Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENLIUS (02696.HK) HLX43 for Injection Combined with Hansizhuang Approved for Phase II Trial in Australia; HLX04-O Phase III Study Meets Primary Endpoint
Recommend 1 Positive 1 Negative 0 |
||||
|
||||
|
HENLIUS (02696.HK) announced that its HLX43 for Injection (a PD-L1-targeting antibody-drug conjugate), in combination with Hansizhuang (serplulimab injection), has recently received approval from the relevant Human Research Ethics Committee for a Phase II clinical trial as neoadjuvant treatment for non-small cell lung cancer (NSCLC). The trial has also completed clinical trial notification filing with the Therapeutic Goods Administration of Australia. The company plans to initiate the relevant clinical trial in Australia once conditions are met. In addition, the company’s recombinant anti-VEGF humanized monoclonal antibody injection HLX04-O (HLX04-O) achieved its primary endpoint in an international multi-center Phase III clinical study conducted in patients with wet age-related macular degeneration (wAMD). (sl/a) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
